Financial Performance - Total Operating Revenues increased by 8.9% to $1.191 billion for the three months ended December 2024, and increased by 22.9% to $4.638 billion for the twelve months ended December 2024[26] - Gaming revenue increased by 8.3% to $972 million for the three months ended December 2024, and increased by 22.6% to $3.773 billion for the twelve months ended December 2024[26] - Non-Gaming revenue increased by 11.8% to $219 million for the three months ended December 2024, and increased by 24.0% to $866 million for the twelve months ended December 2024[26] - Net Loss decreased by 82.4% to $40 million for the three months ended December 2024, and decreased by 93.3% to $28 million for the twelve months ended December 2024[26] - Adjusted Property EBITDA decreased by 2.6% to $295 million for the three months ended December 2024, and increased by 17.0% to $1.220 billion for the twelve months ended December 2024[26] Operational Highlights - City of Dreams Macau's Adjusted EBITDA was $140 million in 4Q'24[29] - Studio City's Adjusted EBITDA was $81 million in 4Q'24, with VIP operations ceasing in late October 2024[33, 36] - Altira recorded negative Adjusted EBITDA of $0.3 million in 4Q'24[37] - City of Dreams Manila's Adjusted EBITDA was $57 million in 4Q'24[41] - City of Dreams Mediterranean and Other recorded Adjusted EBITDA of $12 million in 4Q'24[45] Capital Allocation - Approximately $3.908 billion has been returned to shareholders from 2016 to 2024 through special dividends of $1 billion, regular dividends of $883 million and share repurchases of $2.024 billion[54] - For the year ended December 31, 2024, Melco repurchased approximately 20.7 million ADSs at an aggregate purchase price of approximately $112 million[54] - From January 1, 2025 to February 26, 2025, Melco repurchased 3.7 million ADSs at an aggregate purchase price of approximately $20 million[54]

FOURTH QUARTER 2024 SUPPLEMENTAL RECONCILATION MATERIALS | Year Ended Supplemental Financial Reconciliations Three Mos. Ended, Three Months Ended, Three Months Ended, Three Months Ended, | | | --- | --- | | in millions) December 31, September 30, June 30, March 31, December 31, | ($ | | 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2022 | | | Adjusted EBITDA Reconciliations: | | | Adjusted EBITDA (Current Definition) $ 628 $ 449 $ 510 $ 279 $ 414 $ 361 $ 452 $ 388 $ 2,004 $ 1,477 $ 2,238 | | | Plus: Dis ...

Financial Data and Key Metrics Changes - Ambac reported a net loss of $548 million or $10.23 per diluted share for Q4 2024, compared to a net loss of $16 million or $0.24 per diluted share in Q4 2023 [28] - Consolidated adjusted net loss was $6 million or $0.12 per diluted share for Q4 2024, compared to adjusted net income of $4 million or $0.10 per diluted share in Q4 2023 [30] - The company recorded a $570 million loss on the sale of its legacy financial guarantee business [23] Business Line Data and Key Metrics Changes - The P&C business generated nearly $900 million in premiums, up 74% from 2023, and produced $236 million in revenue, up 89% from the prior year [7] - Cirrata generated nearly $100 million in revenue for 2024, up 93%, and earned approximately $20 million of adjusted EBITDA [15] - Everspan's gross premium written grew to over $380 million, up 40% from the prior year, with a combined ratio of 101.6%, improving nearly 500 basis points over 2023 [20][21] Market Data and Key Metrics Changes - The overall E&S market continues to perform well, with high-single to double-digit rate increases in U.S. casualty lines [12] - The property market showed some softening in Q4, but terms and conditions have held [13] - Professional and financial lines are experiencing softness, particularly in large account and public market D&O [14] Company Strategy and Development Direction - The company is focused on the future growth of its Specialty P&C business and delivering value for shareholders [11] - Ambac aims to achieve strong organic growth and generate $80 million to $90 million of adjusted EBITDA to common shareholders by 2028 [44] - The acquisition of Beat is expected to deliver strong organic growth and enhance the distribution platform [8] Management's Comments on Operating Environment and Future Outlook - Management noted that the areas of softening in the market, such as Employer Stop Loss and short-term medical, may stabilize in the near future [50] - The focus remains on profitability for Everspan, with effective loss ratios in the mid-60s aligning with long-term goals [55] - Management expressed optimism about the prospects for Ambac's future, particularly following the separation from the legacy financial guarantee business [43] Other Important Information - The company has substantially completed the separation of its legacy and P&C businesses, preparing for the close of the legacy sale [11] - Cirrata's premiums increased by 309% to $205 million, with total revenue rising by 257% to $44 million compared to Q4 2023 [31] Q&A Session Summary Question: Distribution business performance and outlook - Management indicated that softening in Employer Stop Loss and short-term medical is a macro trend, but stabilization is expected [50][51] Question: Sustainability of Everspan's combined ratio - Management stated that while there is variability, the performance aligns with long-term objectives, aiming for effective loss ratios in the mid-60s [55][56]

Financial Data and Key Metrics Changes - In 2024, the company achieved a double-digit adjusted EBITDA increase, with a 3% growth in global volumes [6][7] - Adjusted EBITDA for Q4 2024 grew by 11% year-over-year to $164 million, driven by higher sales volumes and production in Europe [8][26] - The company ended the year with nearly $1 billion in liquidity and a reduced net leverage ratio of 4.9 times net debt to adjusted EBITDA [7][21] Business Line Data and Key Metrics Changes - In Europe, revenue increased by 27% to $552 million, with shipments growing by 8% in Q4 [12][14] - Adjusted EBITDA in Europe increased by 81% to $56 million, supported by positive volume growth and stronger input cost recovery [14] - In the Americas, revenue decreased by 7% to $653 million, with adjusted EBITDA decreasing by 1% to $108 million due to lower volumes [15][16] Market Data and Key Metrics Changes - The beverage can continues to gain market share in customers' packaging mix, with expectations for industry shipment growth into 2025 [9][10] - In Brazil, Q4 beverage can shipments decreased by 15% due to a customer mix issue, but excluding this customer, shipments grew by 7% [18][19] - The North American market is expected to see low single-digit percentage growth in shipments in 2025, driven by recovery in the energy category and growth in carbonated soft drinks [17][20] Company Strategy and Development Direction - The company is focused on sustainability, having made significant progress towards renewable electricity targets and reducing greenhouse gas emissions [10][11] - The company anticipates continued growth in adjusted EBITDA in 2025 through increased shipments and operational improvements [9][28] - The company expects to maintain a capital allocation policy consistent with previous years, including a quarterly dividend of $0.10 per share [25][79] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market outlook, projecting global shipment growth of 2% to 3% for 2025 and adjusted EBITDA in the range of $675 million to $695 million [28][29] - Management noted that inflationary pressures and currency headwinds in Europe are expected to partially offset growth [28] - The company remains optimistic about the North American beverage can market, citing strong demand in carbonated soft drinks and alcoholic cocktails [42][72] Other Important Information - The company signed agreements for solar projects in Germany and a virtual power purchase agreement in Portugal, advancing its sustainability agenda [10] - The company recorded a reduction in overall total recordable incident rates and accident severity rates in 2024 [11] Q&A Session Summary Question: Impact of tariffs on demand - Management indicated that the impact on retail prices is minimal, with costs being passed on to consumers, and they expect less impact in 2025 due to hedging [32][34] Question: Performance in the Americas - Management noted improvements in Brazil's volumes and recovery in the energy category in North America, expressing optimism for 2025 [36][38] Question: Growth forecast specifics - Management confirmed expectations for low single-digit growth in North America, driven by strength in carbonated soft drinks and alcoholic cocktails [42][72] Question: Glass to metal substitution trends - Management highlighted a long-term trend of glass to metal substitution in Europe, driven by energy costs and sustainability advantages [60][62] Question: Free cash flow outlook - Management provided guidance on expected cash flow items for 2025, indicating a slight reduction in free cash flow compared to 2024 [74][79] Question: Earnings outlook and volume growth - Management explained that headwinds from aluminum conversion costs and PPI in Europe would affect the translation of volume growth into EBITDA [102][104]

Core Insights - Endeavor Group reported $1.57 billion in revenue for the quarter ended December 2024, reflecting a year-over-year decline of 0.9% and an EPS of -$0.22 compared to $0.16 a year ago, indicating a significant drop in profitability [1] - The reported revenue exceeded the Zacks Consensus Estimate of $1.5 billion by 4.34%, while the EPS fell short of the consensus estimate of $0.36 by 161.11% [1] Revenue Breakdown - Revenue from Owned Sports Properties was $670.41 million, surpassing the average estimate of $654.45 million by analysts, marking a year-over-year increase of 4.3% [4] - Revenue from Eliminations was reported at -$15.65 million, better than the average estimate of -$27.86 million, with a year-over-year change of 0.8% [4] - Revenue from Representation reached $501.63 million, exceeding the average estimate of $462.86 million, representing a year-over-year increase of 17.4% [4] - Revenue from Events, Experiences & Rights was $411.88 million, slightly below the average estimate of $413.10 million, showing a year-over-year decline of 0.6% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Corporate was -$79.40 million, worse than the average estimate of -$77.07 million [4] - Adjusted EBITDA for Representation was $108.18 million, falling short of the average estimate of $119.07 million [4] - Adjusted EBITDA for Events, Experiences & Rights was $11.02 million, significantly below the average estimate of $66.47 million [4] - Adjusted EBITDA for Owned Sports Properties was $237.25 million, compared to the average estimate of $276.18 million, indicating underperformance [4] Stock Performance - Endeavor's shares have returned +1.4% over the past month, contrasting with the Zacks S&P 500 composite's -2.2% change, suggesting relative strength in the stock [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, ...

Core Insights - Golar LNG Limited has maintained a strong operational track record with FLNG Hilli, exceeding its contracted production volume for 2024, resulting in $0.5 million of overproduction revenue recognized [1] - The acquisition of remaining minority interests in FLNG Hilli for $60 million in cash and an increase in contractual debt has resulted in Golar holding a 100% economic interest in FLNG Hilli [2] - The acquisition is expected to increase Golar's annual Adjusted EBITDA by approximately $7 million, with additional revenue linked to Brent oil and TTF gas prices [3] Financial Performance - For Q4 2024, Golar reported a net income of $3 million, with an Adjusted EBITDA of $59 million, while the full year 2024 net income was $50 million and Adjusted EBITDA was $241 million [6] - Total Golar Cash as of December 31, 2024, was $699 million, consisting of $566 million in cash and cash equivalents and $133 million in restricted cash [22] - Golar's share of contractual debt increased to $1.515 billion as of December 31, 2024, reflecting a 24% increase from the previous year [17] Operational Developments - FLNG Gimi has commenced commissioning, with the first LNG export cargo expected in Q1 2025, and the Commercial Operations Date anticipated in Q2 2025 [5][7] - The MKII FLNG conversion project is on schedule, with $0.6 billion spent to date, and is expected to be delivered in Q4 2027 [8] - Golar has entered into definitive agreements for the deployment of FLNG in Argentina, with a consortium of leading gas producers involved [10] Future Outlook - Golar expects to release significant capital from refinancing FLNG Hilli following the completion of conditions precedent in the SESA 20-year charter [4] - The project in Argentina is projected to generate an annual Adjusted EBITDA of approximately $300 million, plus commodity-linked revenue [11] - Golar is in advanced discussions for additional FLNG units and has options for further conversions at CIMC shipyard [13]

Financial Data and Key Metrics Changes - The company reported a 28% revenue growth for Q4 2024, reaching $24.7 million compared to $19.4 million in Q4 2023 [16] - Gross profit for Q4 2024 was $15.5 million, a 22% increase from $12.7 million in Q4 2023, with gross margins at 62.7% [17] - The operating loss decreased by 27% to $4.6 million, while the net loss decreased by 36% to $6.8 million [18][19] - Adjusted EBITDA improved by 68% to negative $1.4 million from negative $4.4 million in Q4 2023 [20] Business Line Data and Key Metrics Changes - Total billable volume for Q4 was approximately 24,000 tests, a 26% increase [8] - Tissue-based tests, including Confirm mdx and GPS, saw a 50% increase year-over-year, totaling almost 12,000 tests in Q4 [9] - Liquid-based tests, including Select mdx, Resolve mdx, and Germline, exceeded 12,000 tests, marking a 10% increase year-over-year [9] Market Data and Key Metrics Changes - The urology diagnostic market is expected to grow at an annual rate of 5% to 10% due to factors such as increasing prostate cancer rates and an aging population [25] - The company is positioned uniquely in the market, providing clinically actionable results after initial biopsy, which is expected to drive further growth [11] Company Strategy and Development Direction - The company aims to achieve a revenue guidance of $108 million to $110 million for 2025, maintaining a goal of 20% revenue growth [14] - The focus remains on execution and leveraging existing sales channels without expanding the sales organization [12][24] - The company emphasizes building a trusted brand in the urology market through high-quality service and customer support [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA in the first half of 2025 [20][84] - The company is optimistic about the adoption of its tests and the overall growth trajectory, despite challenges in the diagnostic pathway for patients [12][66] - Management noted that the NCCN guidelines created confusion but did not negatively impact growth, as evidenced by accelerating test volumes [44] Other Important Information - Cash and cash equivalents as of December 31, 2024, were $46.8 million, with plans to strengthen the balance sheet through a pending draw from the OrbiMed debt facility [21] - The company has a structured plan for the Germline test, expecting it to contribute to growth in 2025, albeit conservatively [31] Q&A Session Summary Question: Contribution of Germline to 2025 growth - Management is confident that Germline will contribute to growth in 2025, following a conservative approach similar to the Resolve test [31] Question: Outlook on gross margins - Management does not provide specific guidance on gross margins but expects them to remain in the mid-60s for the next few quarters [34] Question: OpEx outlook and adjusted EBITDA - Management indicated that the growth strategy remains unchanged, with no significant changes in OpEx expected as the business begins to fund itself [40][41] Question: Impact of NCCN guidelines on business - Management noted that the NCCN guidelines created confusion but did not negatively impact growth, with strong channel checks supporting their position [44] Question: Test menu breadth and new additions - Management believes the current test menu is sufficient to meet growth objectives, with no immediate plans for new test additions in 2025 [51][54] Question: Impact of Medicare reimbursement on commercial coverage - Management reported solid growth across the test menu, with expectations for continued expansion of coverage with commercial and private payers [57] Question: Timing of Exact Sciences earn-out payments - The earn-out payments to Exact Sciences are expected to occur in Q2 each year for 2025, 2026, and 2027 [88]

Earnings presentation Fourth quarter and full year 2024 $1.30 back Add offer Some of the financial information and data contained in this presentation, such as Non-GAAP direct-to-consumer redemption revenue, Non-GAAP redemption revenue, Non-GAAP direct-to-consumer redemption revenue per redemption, Non-GAAP total revenue, Non- GAAP redemption revenue per redemption, Adjusted EBITDA, Adjusted EBITDA margin, Non-GAAP gross profit, Non-GAAP operating expenses as a percentage of Non-GAAP revenue, Non-GAAP sales ...

National Health Investors Q4 2024 Supplemental TABLE OF CONTENTS COMPANY | COMPANY INFORMATION & LEADERSHIP | 02 | | --- | --- | | PORTFOLIO | | | PORTFOLIO OVERVIEW | 03 | | REAL ESTATE INVESTMENTS | 04 | | SENIOR HOUSING OPERATING PORTFOLIO | 05 | | OPERATING PARTNERS | 06 | | EBITDARM LEASE COVERAGE & OCCUPANCY | 07 | | PURCHASE OPTIONS & LEASE MATURITIES | 08 | | INVESTMENTS | | | INVESTMENT RATIONALE | 09 | | RECENT INVESTMENTS | 10 | | CAPITALIZATION | | | CAPITALIZATION OVERVIEW | 11 | | CAPITAL STRU ...